CSIMarket
 
Cannapharmarx Inc   (CPMD)
Other Ticker:  
 
 
Price: $0.0125 $0.00 -16.667%
Day's High: $0.015 Week Perf: -35.9 %
Day's Low: $ 0.01 30 Day Perf: 594.44 %
Volume (M): 4,327 52 Wk High: $ 0.02
Volume (M$): $ 54 52 Wk Avg: $0.01
Open: $0.01 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Cannapharmarx Inc
Cannapharmarx Inc is a pharmaceutical company that specializes in the research and development of medical cannabis and related products. The company focuses on creating innovative solutions to improve the health and well-being of patients through the use of cannabis-based medicines. Cannapharmarx Inc is committed to conducting extensive research, clinical trials, and rigorous quality control processes to ensure safe and effective products. They aim to provide healthcare professionals and patients with reliable treatments that harness the therapeutic properties of cannabis.


   Company Address: Suite 3600 Calgary 0 AB
   Company Phone Number: 652-6838   Stock Exchange / Ticker: CPMD
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Cannapharmarx Inc

Cannapharmarx Inc Dominates Third Quarter of 2023, Outperforming Competitors with Impressive Results



Cannapharmarx Inc, an emerging leader in the pharmaceutical industry, has provided an update on its financial performance for the July to September 2023 reporting cycle. While shareholders were not expecting significant changes in revenue, attention was drawn to the company's operating loss, which improved compared to the previous year. Additionally, a surge in accounts receivable suggests a growing demand for Cannapharmarx's products. This article delves into the details of the company's financials and discusses its potential for success in the market.
Operating Loss Improvement
During the July to September reporting cycle, Cannapharmarx Inc recorded an operating loss of $-0.667497 million. While this is still a loss, it is essential to note that the company's operating loss has consistently decreased over the past year. In the third quarter of 2022, the operating loss stood at $-0.588475 million, demonstrating a gradual reduction. The most recent financials indicate further progress, with the operating loss narrowing to $-0.564 million. This positive trend bodes well for Cannapharmarx Inc as it strives to become a successful leader in the industry.

Cannapharmarx Inc

Cannapharmarx Inc Sees Strong Business Growth in Q2 of 2023 Financial Period



Cannapharmarx Inc's second-quarter earnings report for the period of April to June 2023 has left stockholders somewhat unsurprised. As anticipated, there haven't been any significant changes at the top-line during this earnings season. However, closer attention has been paid to the company?s operating shortfall, which amounted to a substantial $-0.892939 million during the same time frame.
The operating shortfall is a crucial measure used to frame the financial performance of any organization. In this case, it signifies the financial period ending the second quarter of 2023's results for Cannapharmarx Inc, providing a snapshot of its current standing.

Cannapharmarx Inc

Cannapharmarx Inc. Shows Promising Results with Reduced Losses and Growing Revenue in First Quarter of 2023



The first quarter of 2023 has shown significant promise for Cannapharmarx Inc, a major player in the pharmaceutical preparations industry. While the company has not revealed any top-line figures yet, industry observers are examining the operating shortfall of $-0.720277 million, shedding light on the positive performance of the firm during this period. By comparing it to previous quarters and assessing other growth indicators, we can anticipate a bullish outlook for Cannapharmarx Inc in the near future.
Reduced Losses and Growing Revenue:
In the first quarter of 2022, Cannapharmarx Inc experienced an operating shortfall of $-0.715558 million. However, with effective cost-cutting measures and revenue growth strategies, the company has managed to improve its financial performance in Q1 2023. The company's losses of $-2.072 million in the first quarter of 2022 have been reduced to $-1.413 million, showcasing a significant improvement in their bottom line. This reduction of losses is indicative of a more efficient and profitable operation.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com